These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 28905173)

  • 1. Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.
    Prathipati PK; Mandal S; Pon G; Vivekanandan R; Destache CJ
    Pharm Res; 2017 Dec; 34(12):2749-2755. PubMed ID: 28905173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic delivery of bictegravir and tenofovir alafenamide using dissolving microneedles for HIV preexposure prophylaxis.
    Zhang C; Wu Y; Hutton ARJ; Hidayat Bin Sabri A; Hobson JJ; Savage AC; McCarthy HO; Paredes AJ; Owen A; Rannard SP; Donnelly RF
    Int J Pharm; 2024 Jul; 660():124317. PubMed ID: 38851410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention.
    Riddler SA; Kelly CW; Hoesley CJ; Ho KS; Piper JM; Edick S; Heard F; Doncel GF; Johnson S; Anderson PL; Brand RM; Kunjara Na Ayudhya RP; Bauermeister JA; Hillier SL; Hendrix CW
    J Infect Dis; 2024 Sep; 230(3):696-705. PubMed ID: 38655842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.
    Kraft JC; McConnachie LA; Koehn J; Kinman L; Sun J; Collier AC; Collins C; Shen DD; Ho RJY
    J Control Release; 2018 Apr; 275():229-241. PubMed ID: 29432823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
    Prathipati PK; Mandal S; Destache CJ
    J Pharm Biomed Anal; 2016 Sep; 129():473-481. PubMed ID: 27497648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency Virus Infection With Tenofovir Alafenamide Fumarate/Elvitegravir Inserts in Macaques.
    Makarova N; Singletary T; Peet MM; Mitchell J; Bachman S; Holder A; Dinh C; Lipscomb J; Agrahari V; Mendoza M; Pan Y; Heneine W; Clark MR; García-Lerma JG; Doncel GF; Smith JM
    J Infect Dis; 2024 Jun; 229(6):1791-1795. PubMed ID: 38134382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments.
    Perazzolo S; Mandal S; Prathipati PK; Destache CJ
    Front Pharmacol; 2020; 11():603242. PubMed ID: 33390993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
    Gunawardana M; Remedios-Chan M; Sanchez D; Fanter R; Webster S; Webster P; Moss JA; Trinh M; Beliveau M; Ramirez CM; Marzinke MA; Kuo J; Gallay PA; Baum MM
    Pharm Res; 2023 Jul; 40(7):1657-1672. PubMed ID: 36418671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.
    Sizovs A; Pons-Faudoa FP; Malgir G; Shelton KA; Bushman LR; Chua CYX; Anderson PL; Nehete PN; Sastry KJ; Grattoni A
    Int J Pharm; 2020 Sep; 587():119623. PubMed ID: 32663582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles.
    Cobb DA; Smith N; Deodhar S; Bade AN; Gautam N; Shetty BLD; McMillan J; Alnouti Y; Cohen SM; Gendelman HE; Edagwa B
    Nat Commun; 2021 Sep; 12(1):5458. PubMed ID: 34531390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Tenofovir Alafenamide Fumarate and Its Metabolite Tenofovir in Healthy Chinese Volunteers.
    Ji X; Li Y; Wang Z; Gao Y; Wang L
    Clin Pharmacol Drug Dev; 2024 Feb; 13(2):168-179. PubMed ID: 37953690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates.
    Pons-Faudoa FP; Di Trani N; Capuani S; Hernandez N; Wood AM; Nehete B; Niles J; Shelton KA; Kezar S; Bushman LR; Chua CYX; Ittmann MM; Anderson PL; Nehete PN; Arduino RC; Nichols JE; Grattoni A
    J Control Release; 2023 Jun; 358():116-127. PubMed ID: 37120032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly Oral Tenofovir Alafenamide Protects Macaques from Vaginal and Rectal Simian HIV Infection.
    Massud I; Nishiura K; Ruone S; Holder A; Dinh C; Lipscomb J; Mitchell J; Khalil GM; Heneine W; Garcia-Lerma JG; Dobard CW
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention.
    Peet MM; Agrahari V; Clark MR; Doncel GF
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aluminium oxide nanoparticles on long-acting oleogels laden with Sc-PLA-chitosan nanoparticles for anti-HIV therapy.
    Narayanan VHB; Durai R; Gonciarz W; Brzezinski M
    Int J Biol Macromol; 2024 Jul; 273(Pt 1):132829. PubMed ID: 38844278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP).
    Li L; Johnson LM; Krovi SA; Demkovich ZR; van der Straten A
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33167509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically based Pharmacokinetic Model Validated to Enable Predictions Of Multiple Drugs in a Long-acting Drug-combination Nano-Particles (DcNP): Confirmation with 3 HIV Drugs, Lopinavir, Ritonavir, and Tenofovir in DcNP Products.
    Perazzolo S; Shen DD; Scott AM; Ho RJY
    J Pharm Sci; 2024 Jun; 113(6):1653-1663. PubMed ID: 38382809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant.
    Pons-Faudoa FP; Trani ND; Sizovs A; Shelton KA; Momin Z; Bushman LR; Xu J; Lewis DE; Demaria S; Hawkins T; Rooney JF; Marzinke MA; Kimata JT; Anderson PL; Nehete PN; Arduino RC; Sastry KJ; Grattoni A
    Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33080776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis.
    Gunawardana M; Remedios-Chan M; Sanchez D; Webster S; Galvan P; Fanter R; Castonguay AE; Webster P; Moss JA; Kuo J; Gallay PA; Vincent KL; Motamedi M; Weinberger D; Marzinke MA; Hendrix CW; Baum MM
    Front Pharmacol; 2020; 11():569373. PubMed ID: 33536904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an extended action fostemsavir lipid nanoparticle.
    Islam F; Das S; Ashaduzzaman M; Sillman B; Yeapuri P; Nayan MU; Oupický D; Gendelman HE; Kevadiya BD
    Commun Biol; 2024 Jul; 7(1):917. PubMed ID: 39080401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.